TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of TK216 and decitabine when given
together in treating patients with acute myeloid leukemia that has come back or does not
respond to treatment. Drugs used in chemotherapy, such as TK216 and decitabine, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading.